Front line treatment of elderly multiple myeloma in the era of novel agents

References

• JemalAMurrayTWardECancer statisticsCA Cancer J Clin200555103015661684
   PubMed Web of Science ®Google Scholar
• KyleRARajkumarSVMultiple myelomaN Engl J Med200435118607315509819
   PubMed Web of Science ®Google Scholar
• JawedILeeCMTwardJDSurvival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis. (#8019)J Clin Oncol 2007, ASCO Annual Meeting Proceedings. No. 18S (June 20 Supplement)200725Part I
   Web of Science ®Google Scholar
• AnagnostopoulosAGikaDSymeonidisAMultiple myeloma in elderly patients: prognostic factors and outcomeEur J Haematol200575370516191085
   PubMed Web of Science ®Google Scholar
• LudwigHDurieBGBolejackVMyeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working GroupBlood200811140394718268097
   PubMed Web of Science ®Google Scholar
• LudwigHZojerNSupportive care in multiple myelomaBest Pract Res Clin Haematol2007208173518070721
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLStoppaAMA prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du MyelomeN Engl J Med19963359178649495
   PubMed Web of Science ®Google Scholar
• BadrosABarlogieBSiegelEAutologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 yearsBr J Haematol2001114600711552985
   PubMed Web of Science ®Google Scholar
• JantunenEItalaMJuvonenEAutologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin’s lymphoma: a nation-wide analysisBone Marrow Transplant2006373677216415893
   PubMed Web of Science ®Google Scholar
• AlexanianRHautAKhanAUTreatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimensJAMA1969208168055818682
   PubMed Web of Science ®Google Scholar
• BatailleRHarousseauJLMultiple myelomaN Engl J Med19973361657649171069
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYPegourieBDexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapyBlood20061071292816174762
   PubMed Web of Science ®Google Scholar
• GroupMTCCombination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists’ Collaborative GroupJ Clin Oncol1998163832429850028
   PubMed Web of Science ®Google Scholar
• AlexanianRDimopoulosMADelasalleKPrimary dexamethasone treatment of multiple myelomaBlood199280887901498331
   PubMed Web of Science ®Google Scholar
• HernandezJMGarcia-SanzRGolvanoERandomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myelomaBr J Haematol20041271596415461621
   PubMed Web of Science ®Google Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med199934115657110564685
   PubMed Web of Science ®Google Scholar
• PalumboABertolaAMustoPOral melphalan, prednisone, and thalidomide for newly diagnosed patients with myelomaCancer200510414283316116606
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSCaravitaTOral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialLancet20063678253116530576
   PubMed Web of Science ®Google Scholar
• FaconTMaryJYHulinCMelphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trialLancet200737012091817920916
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSLiberatiAMOral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized, controlled trialBlood200810.1182/blood-2008-04149427
   Google Scholar
• HulinCFaconTRodonPMelphalan-prednisone-thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients ≥75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01Blood2007110
   Web of Science ®Google Scholar
• WaageAGimsingPJuliussonGMelphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trialBlood2008110
   Web of Science ®Google Scholar
• WijermansPSchaafsmaPVan NordenYMelphalan Prednisone versus Melphalan Prednisone Thalidomide in induction therapy for Multiple Myeloma in Elderly patients: First interim results of the Dutch cooperative group HOVON. (#0440)Haematologica200893s117818223279
   PubMed Web of Science ®Google Scholar
• PalumboAFaconTSonneveldPThalidomide for treatment of multiple myeloma: 10 years laterBlood200811139687718245666
   PubMed Web of Science ®Google Scholar
• PalumboARajkumarSVDimopoulosMAPrevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia2008224142318094721
   PubMed Web of Science ®Google Scholar
• Pineda-RomanMBarlogieBAnaissieEHigh-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patientsCancer200811217546418300230
   PubMed Web of Science ®Google Scholar
• StephensTDBundeCJFillmoreBJMechanism of action in thalidomide teratogenesisBiochem Pharmacol20005914899910799645
   PubMed Web of Science ®Google Scholar
• MatthewsSJMcCoyCThalidomide: a review of approved and investigational usesClin Ther2003253429512749503
   PubMed Web of Science ®Google Scholar
• GhobrialIMDispenzieriABundyKLEffect of thalidomide on stem cell collection and engraftment in patients with multiple myelomaBone Marrow Transplant2003325879212953131
   PubMed Web of Science ®Google Scholar
• BarlogieBDesikanREddlemonPExtended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patientsBlood200198492411435324
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSGertzMACombination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaJ Clin Oncol20022043192312409330
   PubMed Web of Science ®Google Scholar
• ZangariMSiegelEBarlogieBThrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapyBlood200210011687112149193
   PubMed Web of Science ®Google Scholar
• ZangariMAnaissieEBarlogieBIncreased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapyBlood20019816145811520815
   PubMed Web of Science ®Google Scholar
• CavalettiGBeronioAReniLThalidomide sensory neurotoxicity: a clinical and neurophysiologic studyNeurology2004622291315210898
   PubMed Web of Science ®Google Scholar
• RichardsonPSchlossmanRJagannathSThalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activityMayo Clin Proc2004798758215244383
   PubMed Web of Science ®Google Scholar
• MileshkinLStarkRDayBDevelopment of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoringJ Clin Oncol20062445071416940275
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med200334826091712826635
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med200535224879815958804
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood200310123778012424198
   PubMed Web of Science ®Google Scholar
• BerensonJRYangHHSadlerKPhase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJ Clin Oncol2006249374416418495
   PubMed Web of Science ®Google Scholar
• MateosMVHernandezJMHernandezMTBortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II studyBlood200610821657216772605
   PubMed Web of Science ®Google Scholar
• MateosMVHernandezJMHernandezMTBortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progressionHaematologica200893560518322252
   PubMed Web of Science ®Google Scholar
• San MiguelJSchlagRKhuagevaNMMY-3002: A Phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myelomaBlood2007110
   Web of Science ®Google Scholar
• RichardsonPAndersonKImmunomodulatory analogs of thalidomide: an emerging new therapy in myelomaJ Clin Oncol2004223212415249587
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood20029945253012036884
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLWellerEImmunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood20021003063712384400
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSLacyMQCombination therapy with CC-5013 (Lenalidomide, RevlimidTM) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM)Blood200410498a
   Web of Science ®Google Scholar
• PalumboAFalcoPFalconeAOral Revlimid® plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma: results of a multicenter phase I/II studyBlood2007108
   Web of Science ®Google Scholar
• RajkumarSVBloodEVesoleDPhase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200624431616365178
   PubMed Web of Science ®Google Scholar
• LudwigHTothovaEHajekRThalidomide-dexamethasone vs melphalan-prednisone as first line treatment and thalidomide-interferon vs interferon maintenance therapy in elderly patients with multiple myelomaBlood2007110
   Web of Science ®Google Scholar
• OffidaniMCorvattaLMarconiMLow-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II studyHaematologica200691133616434383
   PubMed Web of Science ®Google Scholar
• KyriakouCThomsonKD’SaSLow-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myelomaBr J Haematol20051297637015953002
   PubMed Web of Science ®Google Scholar
• PalumboAGiacconeLBertolaALow-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myelomaHaematologica20018639940311325646
   PubMed Web of Science ®Google Scholar
• ColemanMLeonardJLyonsLBLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom’s macroglobulinemiaLeuk Lymphoma20024317778212685831
   PubMed Web of Science ®Google Scholar
• RajkumarSJacobusSCallanderNA randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology GroupBlood2007110
   Web of Science ®Google Scholar
• HarousseauJLMaintenance treatment in multiple myelomaAnn Oncol200819Suppl 4iv545
   Google Scholar
• AlexanianRBalcerzakSBonnetJDPrognostic factors in multiple myelomaCancer19753611922011175123
   PubMed Web of Science ®Google Scholar
• BelchAShelleyWBergsagelDA randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patientsBr J Cancer1988579493279997
   PubMed Web of Science ®Google Scholar
• FritzELudwigHInterferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patientsAnn Oncol20001114273611142483
   PubMed Web of Science ®Google Scholar
• SchaarCGKluin-NelemansHCTe MarveldeCInterferon-alpha as maintenance therapy in patients with multiple myelomaAnn Oncol200516634915741226
   PubMed Web of Science ®Google Scholar
• BerensonJRCrowleyJJGroganTMMaintenance therapy with alternate-day prednisone improves survival in multiple myeloma patientsBlood2002993163811964279
   PubMed Web of Science ®Google Scholar
• ShustikCBelchARobinsonSA randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7Br J Haematol20071362031117233817
   PubMed Web of Science ®Google Scholar
• BarlogieBTricotGAnaissieEThalidomide and hematopoietic-cell transplantation for multiple myelomaN Engl J Med200635410213016525139
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLLeyvrazSMaintenance therapy with thalidomide improves survival in patients with multiple myelomaBlood200610832899416873668
   PubMed Web of Science ®Google Scholar
• SpencerAPrinceHMRobertsAThalidomide improves survival when used following ASCTHaematologica200792Suppl 2S7b.5
   Google Scholar
• AbdelkefiALadebSTorjmanLSingle autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trialBlood200811118051017875806
   PubMed Web of Science ®Google Scholar
• HusseinMJakubowiakAJBolejackVS0204: Melphalan (MEL)-based tandem autotransplants (TAT) for multiple myeloma (MM) with thalidomide/dexamethasone (TD) induction and thalidomide/prednisone (TP) maintenance: A phase II trial of the Southwest Oncology GroupBlood2006108
   Web of Science ®Google Scholar
• GoldschmidtHSonneveldPCremerFWJoint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patientsAnn Hematol200382654912845480
   PubMed Web of Science ®Google Scholar
• LudwigHPohlGOsterborgAAnemia in multiple myelomaClin Adv Hematol Oncol200422334116163188
   PubMedGoogle Scholar
• LeighBRKurttsTAMackCFRadiation therapy for the palliation of multiple myelomaInt J Radiat Oncol Biol Phys19932580147683017
   PubMed Web of Science ®Google Scholar
• SpinazzeSCaraceniASchrijversDEpidural spinal cord compressionCrit Rev Oncol Hematol20055639740616310372
   PubMed Web of Science ®Google Scholar
• YehHSBerensonJRTreatment for myeloma bone diseaseClin Cancer Res20061220 Pt 26279s84s17062714
   PubMed Web of Science ®Google Scholar
• KimmelDBMechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonatesJ Dent Res20078610223317959891
   PubMed Web of Science ®Google Scholar
• RussellRGXiaZDunfordJEBisphosphonates: an update on mechanisms of action and how these relate to clinical efficacyAnn N Y Acad Sci200711172095718056045
   PubMed Web of Science ®Google Scholar
• MustoPFalconeASanpaoloGPamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trialLeuk Lymphoma2003441545814565658
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039817354414534891
   PubMed Web of Science ®Google Scholar
• StooplerETVoglDTStadtmauerEAMedical management update: multiple myelomaOral Surg Oral Med Oral Pathol Oral Radiol Endod200710359960917291793
   PubMed Web of Science ®Google Scholar
• BerensonJRLichtensteinAPorterLLong-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal eventsMyeloma Aredia Study Group J Clin Oncol199816593602
   PubMed Web of Science ®Google Scholar
• BamiasAKastritisEBamiaCOsteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factorsJ Clin Oncol2005238580716314620
   PubMed Web of Science ®Google Scholar
• DurieBGKatzMCrowleyJOsteonecrosis of the jaw and bisphosphonatesN Engl J Med200535399102 Discussion 199–20216000365
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEAnagnostopoulosAOsteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acidHaematologica2006919687116757414
   PubMed Web of Science ®Google Scholar
• LacyMQDispenzieriAGertzMAMayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMayo Clin Proc20068110475316901028
   PubMed Web of Science ®Google Scholar
• KyleRAYeeGCSomerfieldMRAmerican Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myelomaJ Clin Oncol20072524647217515569
   PubMed Web of Science ®Google Scholar
• OsterborgABoogaertsMACiminoRRecombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma – a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s LymphomaBlood1996872675828639883
   PubMed Web of Science ®Google Scholar
• BokemeyerCAaproMSCourdiAEORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEur J Cancer2007432587017182241
   PubMed Web of Science ®Google Scholar
• KnightRDeLapRJZeldisJBLenalidomide and venous thrombosis in multiple myelomaN Engl J Med200635420798016687729
   PubMed Web of Science ®Google Scholar
• MenonSPRajkumarSVLacyMThromboembolic events with lenalidomide-based therapy for multiple myelomaCancer20081121522818278812
   PubMed Web of Science ®Google Scholar